Literature DB >> 20164031

Effect of arsenic trioxide (Trisenox) on actin organization in K-562 erythroleukemia cells.

Magdalena Izdebska1, Alina Grzanka, Maciej Ostrowski, Agnieszka Zuryń, Dariusz Grzanka.   

Abstract

Actin is one of the cytoskeletal proteins that take part in many cellular processes. The aim of this study was to show the influence of Trisenox (arsenic trioxide), on the cytoplasmic and nuclear F-actin organization. Arsenic trioxide is the proapoptotic factor. Together with increasing doses, it caused the increase in the number of cells undergoing apoptosis. Under arsenic trioxide treatment, cytoplasmic and nuclear F-actin (polymerized form of G-actin) was found reorganized. It was transformed into granulated structures. In cytometer studies fluorescence intensity of cytoplasmic F-actin after ATO treatment decreasing urgently in comparison to control. The obtained results may suggest the involvement of F-actin in apoptosis, especially in chromatin reorganization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20164031     DOI: 10.2478/v10042-009-0080-5

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  3 in total

Review 1.  From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

Authors:  Sai-Juan Chen; Guang-Biao Zhou; Xiao-Wei Zhang; Jian-Hua Mao; Hugues de Thé; Zhu Chen
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  Tetramethylpyrazine potentiates arsenic trioxide activity against HL-60 cell lines.

Authors:  Yuni Wu; Youhua Xu; Yali Shen; Cuicui Wang; Gaili Guo; Tiantian Hu
Journal:  Braz J Med Biol Res       Date:  2012-02-16       Impact factor: 2.590

Review 3.  The Role of Actin Dynamics and Actin-Binding Proteins Expression in Epithelial-to-Mesenchymal Transition and Its Association with Cancer Progression and Evaluation of Possible Therapeutic Targets.

Authors:  Magdalena Izdebska; Wioletta Zielińska; Dariusz Grzanka; Maciej Gagat
Journal:  Biomed Res Int       Date:  2018-01-16       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.